Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. 2008 Exclusive Survey—Earnings: Good news for primary care income 3. Medicare pay-for-reporting effort draws fire from frustrated doctors 4. Debunking Myths in the US Healthcare System 5. EGFR inhibitors as first-line therapy in advanced non-small cell lung cancer
Your Article Summary
Rivaroxaban: An Oral Direct Factor Xa Inhibitor for the Prevention of Thromboembolism
Cardiology In Review, 06/19/09
Chen T et al. - Rivaroxaban is a novel oral direct factor Xa inhibitor. Rivaroxaban has been shown to have tolerable adverse effects and a low potential for drug-drug or drug-food interactions. It has the major advantages of once daily oral dosing and no required laboratory monitoring, giving it the potential to replace current antithrombotics in the market today.
Today in CV/Thromboembolic...keeping you current
Receive free subspecialty "5-minute updates" via email
Is pulmonary arterial hypertension really a late complication of systemic sclerosis
Chest, 10/09/09
The Use of Sildenafil in Persistent Pulmonary Hypertension of the Newborn
American Journal of Perinatology, 10/28/09
Continuous Positive Airway Pressure vs. Pressure Support Ventilation in Acute Cardiogenic Pulmonary Edema: A Randomized Trial
The Journal of Emergency Medicine, 10/13/09
Today in Clinical Pharmacology...keeping you current
Receive free subspecialty "5-minute updates" via email
Intravenous Sildenafil in the Treatment of Neonates with Persistent Pulmonary Hypertension
The Journal of Pediatrics, 10/19/09
An Umbrella Review: Corticosteroid Therapy for Adults with Acute Asthma
American Journal of Medicine, 10/27/09
Magnesium sulphate in the treatment of acute asthma: evaluation of current practice in adult emergency departments
Emergency Medicine Journal, 10/27/09
Sponsor
Article Search
Sponsor


See Latest Articles


